Sartorius Stedim Biotech (OTCMKTS:SDMHF) Trading Down 2.5% – Here’s Why

Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF) fell 2.5% during mid-day trading on Thursday . The company traded as low as $230.00 and last traded at $230.00. 77 shares were traded during trading, a decline of 95% from the average session volume of 1,520 shares. The stock had previously closed at $235.80.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SDMHF. The Goldman Sachs Group cut shares of Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a research report on Monday, January 12th. Barclays reaffirmed an “overweight” rating on shares of Sartorius Stedim Biotech in a research note on Tuesday, January 6th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Sartorius Stedim Biotech Trading Down 2.5%

The company’s 50-day moving average price is $243.60 and its 200-day moving average price is $225.80.

Sartorius Stedim Biotech Company Profile

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.